Related Experiment Video
Updated: May 5, 2026
10:34
A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
7.6K
Astrocyte transcriptomic analysis identifies glypican 5 downregulation as a contributor to synaptic dysfunction in
Biorxiv : the Preprint Server for Biology
|November 18, 2024
Summary
Alzheimer
Area of Science:
- Neuroscience
- Cell Biology
- Genetics
Background:
- Synaptic dysfunction is an early indicator of Alzheimer's disease (AD), correlating with cognitive decline.
- Astrocytes play a critical role in regulating synapse formation, maturation, elimination, and overall function.
Purpose of the Study:
- To investigate alterations in synapse-supportive astrocyte functions in Alzheimer's disease.
- To characterize age- and sex-dependent transcriptional changes in astrocytes within AD mouse models.
Main Methods:
- Utilized astrocyte BacTRAP mice to obtain comprehensive hippocampal astrocyte transcriptional data.
- Analyzed two distinct mouse models of Alzheimer's pathology: APPswe/PS1dE9 and Tau P301S.
- Examined sex and age-dependent transcriptional alterations.
Main Results:
- Astrocytes in both AD mouse models showed downregulation of genes crucial for synaptic regulation, including Glypican 5.
- This observed transcriptional signature in mice mirrors findings in human post-mortem AD patient samples.
- Overexpression of Glypican 5 in astrocytes ameliorated early synaptic dysfunction and improved spatial learning in APPswe/PS1dE9 mice.
Conclusions:
- Astrocytic gene expression changes, particularly the downregulation of synapse-related factors like Glypican 5, are implicated in Alzheimer's disease.
- Targeting astrocytic factors presents a potential therapeutic strategy to mitigate synaptic dysfunction in Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35